Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABIO | ARCA biopharma, Inc.

Index- P/E- EPS (ttm)-0.44 Insider Own18.50% Shs Outstand14.41M Perf Week1.99%
Market Cap29.70M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.26M Perf Month0.00%
Income-6.30M PEG- EPS next Q- Inst Own38.60% Short Float / Ratio1.70% / 10.96 Perf Quarter-2.38%
Sales- P/S- EPS this Y50.40% Inst Trans11.35% Short Interest0.24M Perf Half Y-2.84%
Book/sh2.72 P/B0.75 EPS next Y- ROA-14.80% Target Price- Perf Year-11.06%
Cash/sh2.77 P/C0.74 EPS next 5Y- ROE-15.40% 52W Range1.85 - 2.70 Perf YTD-13.50%
Dividend- P/FCF- EPS past 5Y53.60% ROI- 52W High-24.07% Beta1.28
Dividend %- Quick Ratio25.40 Sales past 5Y- Gross Margin- 52W Low10.81% ATR0.04
Employees5 Current Ratio25.40 Sales Q/Q- Oper. Margin- RSI (14)51.00 Volatility1.75% 1.79%
OptionableYes Debt/Eq0.00 EPS Q/Q53.00% Profit Margin- Rel Volume0.67 Prev Close2.06
ShortableYes LT Debt/Eq0.00 EarningsJul 21 AMC Payout- Avg Volume22.09K Price2.05
Recom- SMA200.13% SMA500.33% SMA200-3.23% Volume14,866 Change-0.49%
Date Action Analyst Rating Change Price Target Change
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Jul-21-23 04:25PM
Jul-13-23 11:30AM
Apr-24-23 04:25PM
Feb-24-23 04:20PM
Feb-03-23 10:19AM
04:05PM Loading…
Dec-19-22 04:05PM
Nov-14-22 09:24AM
Oct-28-22 04:15PM
Aug-02-22 04:15PM
Jul-18-22 06:14AM
Jun-21-22 04:05PM
May-05-22 04:15PM
May-02-22 04:15PM
Apr-18-22 04:30PM
Apr-05-22 01:35AM
07:09AM Loading…
Apr-01-22 07:09AM
Mar-31-22 04:15PM
Mar-14-22 04:15PM
Mar-07-22 04:30PM
Feb-08-22 04:21AM
Jan-04-22 08:30AM
Dec-02-21 08:30AM
Nov-20-21 07:01AM
Nov-09-21 04:15PM
Nov-02-21 04:15PM
Oct-29-21 07:03AM
Oct-28-21 04:30PM
Sep-16-21 08:30AM
Aug-16-21 08:05AM
01:15AM Loading…
Aug-12-21 01:15AM
Aug-09-21 08:00AM
Aug-04-21 04:15PM
Jul-28-21 08:00AM
Jul-13-21 08:00AM
Jul-09-21 08:00AM
Jul-08-21 11:20AM
Jul-07-21 08:00AM
Jun-23-21 09:35AM
May-11-21 04:15PM
May-05-21 04:05PM
May-03-21 04:30PM
Mar-18-21 04:30PM
Feb-13-21 01:09AM
Dec-15-20 08:30AM
Dec-09-20 05:40PM
Nov-23-20 12:28PM
Nov-02-20 08:30AM
Oct-07-20 08:30AM
Oct-05-20 04:30PM
Sep-21-20 08:00AM
Aug-17-20 08:49AM
Aug-12-20 08:00AM
Aug-05-20 04:15PM
Jul-07-20 08:30AM
Jun-03-20 09:56AM
Jun-01-20 08:20AM
May-29-20 12:24PM
May-28-20 04:19PM
May-07-20 08:30AM
May-06-20 04:30PM
Feb-18-20 04:30PM
Feb-01-20 08:31AM
Nov-06-19 04:10PM
Nov-03-19 08:47AM
Sep-12-19 08:30AM
Sep-11-19 08:30AM
Sep-04-19 01:37PM
Aug-21-19 09:49AM
Aug-01-19 04:30PM
Jun-04-19 07:09AM
May-13-19 09:00AM
May-08-19 04:30PM
May-01-19 08:30AM
Apr-23-19 08:30AM
Mar-18-19 08:30AM
Mar-06-19 08:00AM
Feb-27-19 04:15PM
Feb-20-19 07:30AM
Jan-16-19 08:30AM
Dec-26-18 11:47AM
Dec-20-18 04:01PM
Nov-14-18 04:30PM
Nov-12-18 08:30AM
Nov-05-18 08:30AM
Oct-10-18 04:16PM
Oct-02-18 08:00AM
Sep-18-18 08:30AM
Aug-09-18 04:15PM
Aug-03-18 09:45AM
Jul-31-18 12:15PM
Jun-19-18 07:05AM
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.